Get notified when STIM files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Elevated Say-On-Pay Opposition (new) — 28% opposition to executive compensation is above typical levels and signals shareholder concern about pay practices.
- Contested Equity Plan Approval (new) — 41% opposition to the new equity incentive plan indicates significant shareholder pushback on dilution or plan structure.
Neuronetics shareholders signal compensation concerns with 28% say-on-pay opposition
Filed May 29, 2026 · Period ending May 28, 2026 · ~1 min read
Key Changes
-
high
Executive compensation received only 70.5% support, with 28% opposition representing 16.5% of shares outstanding—an elevated level that typically warrants board review of pay practices and performance alignment.
Item 5.07 verify on EDGAR → -
high
New equity incentive plan narrowly passed with 58.8% support and 41% opposition (24% of shares outstanding against), indicating significant shareholder concern about dilution or plan terms.
Item 5.07 verify on EDGAR → -
medium
Director elections showed mixed support ranging from 69% to 84%, with three nominees (Cucuz, Rosengarten, Cascella) receiving 30-31% withheld votes, suggesting dissatisfaction with certain board members.
Item 5.07 verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.
Partner
Trade STIM commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 21, 2026 · How we verify